| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accurate biomarker testing key to experimental MetMAb in lung cancer
|
WENDLING, PATRICE
|
|
2011
|
8 |
7 |
p. 329-330
2 p.
|
artikel
|
| 2 |
An aromatase inhibitor for breast cancer prevention: a promising option with barriers to resolve
|
Wickerham, D. Lawrence
|
|
2011
|
8 |
7 |
p. 304-305
2 p.
|
artikel
|
| 3 |
Bevacizumab shows promise for high-risk and recurrent ovarian cancer
|
LONDON, SUSAN
|
|
2011
|
8 |
7 |
p. 332-333
2 p.
|
artikel
|
| 4 |
Crizotinib continues to produce high response rates in ALK+ non-small cell lung cancer
|
OSTERWEIL, NEIL
|
|
2011
|
8 |
7 |
p. 328-329
2 p.
|
artikel
|
| 5 |
Encouraging novel agents for multiple myeloma
|
LONDON, SUSAN
|
|
2011
|
8 |
7 |
p. 330-331
2 p.
|
artikel
|
| 6 |
Exemestane for postmenopausal women at increased risk of breast cancer
|
Abraham, Jame
|
|
2011
|
8 |
7 |
p. 301-303
3 p.
|
artikel
|
| 7 |
Growing copay crisis makes available care unattainable
|
Bosserman, Linda D.
|
|
2011
|
8 |
7 |
p. 299-300
2 p.
|
artikel
|
| 8 |
HPV-related oral cancers rising precipitously
|
WENDLING, PATRICE
|
|
2011
|
8 |
7 |
p. 333-334
2 p.
|
artikel
|
| 9 |
The FDA and Avastin: Will Commissioner Hamburg find a middle road?
|
Sutter, Sue
|
|
2011
|
8 |
7 |
p. 335-336
2 p.
|
artikel
|
| 10 |
Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies
|
Gregory, Stephanie A.
|
|
2011
|
8 |
7 |
p. 311-325
15 p.
|
artikel
|
| 11 |
Vemurafenib and ipilimumab plus dacarbazine extend survival in metastatic melanoma
|
MACNEIL, JANE SALODOF
|
|
2011
|
8 |
7 |
p. 326-328
3 p.
|
artikel
|
Tijdschrift beschrijving